Tom H. Margrain

Oral glycoside supplement (triterpenoid saponins) for early and intermediate stage age-related macular degeneration (SAMADI trial): study protocol for a double masked randomised placebo-controlled feasibility trial

The primary aim of the SAMADI [SAponins for MAcular DIsease] trial is to establish whether treatment of age-related macular degeneration (AMD) with oral saponin supplements is feasible and acceptable to participants. AMD is a progressive disease, which results in the death and dysfunction of cells in the outer re...